A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5946-5955

  Sborov, Douglas W ^a   Nuovo, Gerard J ^b   Stiff, Andrew ^c   Mace, Thomas ^a   Lesinski, Gregory B ^a   Benson, Don M ^a   Efebera, Yvonne A ^a   Rosko, Ashley E ^a   Pichiorri, Flavia ^a   Grever, Michael R ^a   Hofmeister, Craig C ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Phylogeny Inc   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CANCER UPREGULATED GENE 2; CAPSID PROTEIN; CASPASE 3; IMMUNOGLOBULIN LAMBDA CHAIN; JUNCTIONAL ADHESION MOLECULE A; LENALIDOMIDE; M PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PELAREOREP; SYNDECAN 1; UNCLASSIFIED DRUG; VIRUS RNA; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CENPW PROTEIN, HUMAN; F11R PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOLYTIC VIRUS; VIRAL PROTEIN; VIRUS ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOASSAY; IN SITU HYBRIDIZATION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS GENOME; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; RECURRENT DISEASE; RETROVIRIDAE; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; ANTIBODIES, VIRAL; BIOMARKERS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTORS, CELL SURFACE; RECURRENCE; RETROVIRIDAE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 84918581192     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1404     Document Type: Article

References (36)

1. Tyler KL, Fields BN. Reoviruses. In:Fields BN, Knipe DM, Chanock RM, et al. editors. Virology, Second Edition. New York: Raven Press, Ltd.; 1990. p. 1307-28.
2. Bodkin DK, Nibert ML, Fields BN. Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice. J Virol 1989;63:4676-81.
3. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37.
4. Rubin DH, Kornstein MJ, Anderson AO. Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol 1985;53:391-8.
5. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62.
6. Wolf JL, Kauffman RS, Finberg R, Dambrauskas R, Fields BN, Trier JS. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology 1983;85:291-300.
7. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012;20:1998-2003.
8. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9.
9. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
10. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010;16:5564-72.
11. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-77.
12. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012;18:2080-9.
13. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011;17:581-8.
14. Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, et al. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol 2012;25:1333-44.
15. Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012;31:3023-38.
16. Thirukkumaran CM, Shi ZQ, Neri P, Bahlis N, Morris D. Reovirus synergy with proteosome inhibitor carfilzomib and Akt inhibitor perifisone overcomes therapy resistance of multiple myeloma: promising preclinical activity [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association of Cancer Research 2014 Apr 5-9; San Diego, CA Philadelphia (PA): AACR; 2014 Abstract nr 1709.
17. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy 2013;9:413-4.
18. Nuovo GJ. In situ detection of microRNAs in paraffin embedded, formalin fixed tissues and the co-localization of their putative targets. Methods 2010;52:307-15.
19. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD. A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc 2009;4:107-15.
20. White C, Twigger K, Vidal L, De Bono J, Coffey M, Heinemann L,et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.Gene Ther 2008;15:911-20.
21. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
22. Norman KL, Hirasawa K, Yang A-D, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 2004;101:11099-104.
23. Danthi P, Holm G, Stehle T, Dermody T. Reovirus receptors, cell entry, and proapoptotic signaling. In:Pöhlmann S, Simmons G, editors. Viral Entry into Host Cells: Springer New York; 2013. p. 42-71.
24. Bezieau S, Devilder M-C, Avet-Loiseau H, Mellerin M-P, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001;18:212-24.
25. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014;123:632-9.
26. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15:1522-30.
27. Park EH, Park EH, Cho IR, Srisuttee R, Min HJ, Oh MJ, et al. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 2010;17:307-14.
28. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009;15:4374-81.
29. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009;183:4312-21.
30. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018-26.
31. Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Translat Med 2012;4:138ra77-ra77.
32. Russell SJ, Federspiel MJ, Peng K-W, Tong C, Dingli D, Morice WG, et al.Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings; 2014: Elsevier; 2014.
33. Bailey K, Kirk A, Naik S, Nace R, Steele MB, Suksanpaisan L, et al. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PloS ONE 2013;8:e73759.
34. Berry LJ, Au GG, Barry RD, Shafren DR. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate 2008;68:577-87.
35. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
36. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, et al. Preclinical pharmacology and toxicology of intravenous MVNIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-10.